This clinical-stage immunology company develops monoclonal antibodies targeting autoimmune and neuromuscular disorders. Its primary investigational asset, IMVT-1402, is being evaluated for multiple indications including graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus, and Sjögren's disease. The company also develops batoclimab, a neonatal Fc receptor antagonist in clinical testing for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease.
Immunovant operates as a subsidiary of Roivant Sciences Ltd., a clinical-stage biopharmaceutical company. The organization currently does not generate product revenue, as its candidates remain in clinical development stages. The company maintains research and development operations focused on advancing its monoclonal antibody pipeline.
Based in New York, New York, Immunovant operates with approximately 362 full-time employees and is incorporated in Delaware. The company is listed on the Nasdaq exchange and has a market capitalization of $5.6 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-2.73 | $-2.73 | -45.2% | |
| 2024 | $-1.88 | $-1.88 | -9.9% | |
| 2023 | $-1.71 | $-1.71 | -19.6% | |
| 2022 | $-1.43 | $-1.43 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-03-31 | 2025-05-29 | 0001764013-25-000092 | SEC ↗ |
| 2024-03-31 | 2024-05-29 | 0001764013-24-000109 | SEC ↗ |
| 2023-03-31 | 2023-05-22 | 0001764013-23-000065 | SEC ↗ |
| 2022-03-31 | 2022-06-08 | 0001764013-22-000059 | SEC ↗ |
| 2021-03-31 | 2021-06-01 | 0001764013-21-000052 | SEC ↗ |
| 2020-03-31 | 2020-06-29 | 0000950123-20-006444 | SEC ↗ |